Rep. Rick W. Allen Sells Off Shares of Abbott Laboratories (NYSE:ABT)

Representative Rick W. Allen (Republican-Georgia) recently sold shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on June 05th, the Representative disclosed that they had sold between $15,001 and $50,000 in Abbott Laboratories stock on April 16th. The trade occurred in the Representative’s “R.W. ALLEN & ASSOCIATES, INC. > RWA&A – SECURITIES” account.

Representative Rick W. Allen also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of Intuit (NASDAQ:INTU) on 4/16/2026.
• Sold $15,001 – $50,000 in shares of Procter & Gamble (NYSE:PG) on 4/16/2026.
• Sold $15,001 – $50,000 in shares of S&P Global (NYSE:SPGI) on 4/16/2026.
• Sold $50,001 – $100,000 in shares of Ameriprise Financial (NYSE:AMP) on 4/15/2026.

Abbott Laboratories Price Performance

ABT traded up $0.77 during trading on Tuesday, hitting $91.27. 14,108,208 shares of the stock traded hands, compared to its average volume of 11,897,769. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $139.06. The company has a market cap of $158.97 billion, a price-to-earnings ratio of 25.57, a PEG ratio of 1.52 and a beta of 0.63. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. The business has a 50 day moving average price of $92.52 and a 200 day moving average price of $108.88.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, beating the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The business had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. During the same period in the previous year, the business earned $1.09 earnings per share. The company’s revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities research analysts forecast that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Daniel J. Starks acquired 10,000 shares of the business’s stock in a transaction dated Monday, April 27th. The shares were bought at an average price of $92.65 per share, with a total value of $926,500.00. Following the transaction, the director directly owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. This trade represents a 0.15% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Philip P. Boudreau bought 2,200 shares of the stock in a transaction dated Thursday, April 23rd. The shares were purchased at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the transaction, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at $201,300. This trade represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Corporate insiders own 0.46% of the company’s stock.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott secured CE Mark approval for Libre Duo and Libre Duo 10 Day, described as the world’s first dual glucose-ketone sensing technology for people with diabetes. The approval expands Abbott’s diabetes care portfolio and could support future growth in its continuous glucose monitoring business. Article Title
• Positive Sentiment: Goldman Sachs maintained its Buy rating on Abbott Laboratories, which can help reinforce investor confidence after the stock’s recent weakness. Analyst support often matters when sentiment is already focused on valuation and recovery potential. Article Title
• Positive Sentiment: Abbott’s Healthy Food Rx “Food is Medicine” program showed stronger health outcomes when paired with community health worker coaching, including improvements in diabetes management, food insecurity, and physical and mental health. While not a direct earnings driver, it highlights Abbott’s broader healthcare brand and its ability to build programs around chronic disease management. Article Title
• Neutral Sentiment: Abbott was also mentioned in a Motley Fool stock-picking article that called it a “rock-solid” blue-chip name for long-term portfolios. This is broadly supportive of Abbott’s investment image, but it is not company-specific news. Article Title
• Neutral Sentiment: A separate valuation-focused article suggested investors are revisiting whether Abbott is a bargain after its share-price slump. That reinforces the current debate around ABT’s depressed valuation, but it does not add a new catalyst by itself. Article Title
• Negative Sentiment: Abbott remains well below its recent highs and has been under pressure over the past year, so the stock is still trading against a backdrop of weaker longer-term momentum. That context may limit upside until investors see clearer earnings acceleration. Article Title

Analysts Set New Price Targets

Several research analysts have commented on the stock. Sanford C. Bernstein lowered their price objective on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Raymond James Financial lowered their price objective on shares of Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. BTIG Research restated a “buy” rating and set a $131.00 price objective on shares of Abbott Laboratories in a research report on Monday, April 27th. The Goldman Sachs Group decreased their target price on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a research note on Wednesday, May 27th. Finally, Royal Bank Of Canada decreased their target price on shares of Abbott Laboratories from $135.00 to $130.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $119.09.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. MidAtlantic Capital Management Inc. acquired a new position in shares of Abbott Laboratories during the fourth quarter worth $25,000. Cornerstone Financial Management LLC acquired a new stake in Abbott Laboratories in the fourth quarter valued at $25,000. Purpose Unlimited Inc. bought a new position in Abbott Laboratories during the 4th quarter worth $25,000. Portfolio Resources Advisor Group Inc. acquired a new position in Abbott Laboratories during the 4th quarter worth about $26,000. Finally, Abound Financial LLC acquired a new position in Abbott Laboratories during the 4th quarter worth about $26,000. Institutional investors own 75.18% of the company’s stock.

About Representative Allen

Rick Allen (Republican Party) is a member of the U.S. House, representing Georgia’s 12th Congressional District. He assumed office on January 3, 2015. His current term ends on January 3, 2027.

Allen (Republican Party) ran for re-election to the U.S. House to represent Georgia’s 12th Congressional District. He won in the general election on November 5, 2024.

Allen was born in Augusta, Georgia, in 1951. He attended Auburn University in Alabama, graduating in 1973 with a B.S. in building construction.

After earning his degree, Allen worked as an estimator, project administrator and assistant to the president with a construction firm in Augusta. In 1976, he founded his own construction business, R. W. Allen & Associates, Inc. The company operates in six states across the country. In 2008, Allen was presented with the Augusta Metro Chamber of Commerce’s Small Business Person of the Year award.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.